Anesthetic considerations in patients with Alzheimer's disease

Journal of Clinical Anesthesia

Volumn 15, Issue 1, 2003, Pages 52-58

  Fernandez, Christopher R ^a   Fields, Aaron ^a   Richards, Todd ^a   Kaye, Alan David ^a,b  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

^b TEXAS TECH UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Anesthesia; Pathology; Pharmacology

Indexed keywords

ALZHEIMER DISEASE; ANESTHESIST; CONTROLLED STUDY; GENERAL ANESTHESIA; HUMAN; PATHOGENESIS; PHYSIOLOGY; POPULATION GROWTH; PREOPERATIVE PERIOD; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STATISTICAL ANALYSIS;

EID: 0037299097     PISSN: 09528180     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-8180(02)00483-X     Document Type: Review

References (40)

1. Alzheimer A., Stelzmann R.A., Schnitzlein H.N., Murtagh F.R. An English translation of Alzheimer's 1907 paper, "Uber eine eigenartige Erkankung der Hirnrinde" Clin Anat. 8:1995;429-431.
2. Farrer L.A., Myers R.H., Connor L., Cupples L.A., Growdon J.H. Segregation analysis reveals evidence of a major gene for Alzheimer disease. Am J Hum Genet. 48:1991;1026-1033.
3. Breitner J.C., Silverman J.M., Mohs R.C., Davis K.L. Familial aggregation in Alzheimer's disease comparison of risk among relatives of early- and late-onset cases, and among male and female relatives in successive generations . Neurology. 38:1988;207-212.
4. Nagata O., Hanaoka K. Anesthetic management of a patient with Alzheimer's disease. Masui. 42:1993;1043-1046.
5. Sloane P.D., Zimmerman S., Suchindran C., et al. The public health impact of Alzheimer's disease, 2000-2050 potential implication of treatment advances . Annu Rev Public Health. 23:2002;213-231.
6. Minino A.M., Smith B.L. Deaths preliminary data for 2000 . Natl Vital Stat Rep. 49:2001;1-40.
7. DeKosky ST, Orgogozo JM: Alzheimer disease: diagnosis, costs, and dimensions of treatment. Alzheimer Dis Assoc Disord(Suppl 1):S3-7.
8. Calne D.B. Clinical features and natural history of Alzheimer's disease. Calne D. Neurodegenerative Diseases. 1994;634-637 W. B. Saunders Co, Philadelphia.
9. Dobson C.B., Itzhaki R.F. Herpes simplex virus type 1 and Alzheimer's disease. Neurobiol Aging. 20:1999;457-465.
10. Flaten T.P. Aluminium as a risk factor in Alzheimer's disease, with emphasis on drinking water. Brain Res Bull. 55:2001;187-196.
11. Klepak P.B. Study of Alzheimer's and aluminum link flawed. Am Pharm. NS29:1989;6.
12. Saunders A.M. Apolipoprotein E and Alzheimer disease an update on genetic and functional analyses . J Neuropathol Exp Neurol. 59:2000;751-758.
13. Schenk D. Alzheimer's disease. A partner for presenilin. Nature. 407:2000;34-35.
14. Vidal R., Revesz T., Rostagno A., et al. A decamer duplication in the 3′ region of the BRI gene originates an amyloid peptide that is associated with dementia in a Danish kindred. Proc Natl Acad Sci USA. 97:2000;4920-4925.
15. Bohnen N.I., Warner M.A., Kokmen E., Beard C.M., Kurland L.T. Alzheimer's disease and cumulative exposure to anesthesia a case-control study . J Am Geriatr Soc. 42:1994;198-201.
16. Lagercrantz H., Ringstedt T. Organization of the neuronal circuits in the central nervous system during development. Acta Paediatr. 90:2001;707-715.
17. Graf R.A. Detouring destruction a role for inhibitory neuronal activity in preventing neuronal loss-implications for Alzheimer's disease . J Am Osteopath Assoc. 101:(12 Suppl Pt 1):2001;S7-10.
18. Boncristiano S., Calhoun M.E., Kelly P.H., et al. Cholinergic changes in the APP23 transgenic mouse model of cerebral amyloidosis. J Neurosci. 22:2002;3234-3243.
19. Shinotoh H., Nemba H., Fukushi K., et al. Progressive loss of cortical acetylcholinesterase activity in association with cognitive decline in Alzheimer's disease a positron emission tomography study . Ann Neurol. 48:2000;194-200.
20. Tsuchiya K., Ikeda K., Niizato K., et al. Parkinson's disease mimicking senile dementia of the Alzheimer type a clinicopathological study of four autopsy cases . Neuropathology. 22:2002;77-84.
21. Hopper T., Bayles K.A., Kim E. Retained neuropsychological abilities of individuals with Alzheimer's disease. Semin Speech Lang. 22:2001;261-273.
22. Froehlich T.E., Robison J.T., Inouye S.K. Screening for dementia in the outpatient setting the time and change test . J Am Geriatr Soc. 46:1998;1506-1511.
23. Boss M.A. Diagnostic approaches to Alzheimer's disease. Biochim Biophys Acta. 1502:2000;188-200.
24. Winblad B. Long term therapy for Alzheimer's Disease. 1999;9th Congress of the International Psychogeriatric Assoc, Vancouver, BC.
25. Deleu D., Hanssens Y. Donepezil in the treatment of Alzheimer disease. Arch Neurol. 57:2000;1380.
26. Toran-Allerand C.D. Estrogen as a treatment for Alzheimer disease. JAMA. 284:2000;307-308.
27. Thomas T. Monoamine oxidase-B inhibitors in the treatment of Alzheimer's disease. Neurobiol Aging. 21:2000;343-348.
28. Le Bars P.L., Velasco F.M., Ferguson J.M., Dessain E.C., Kieser M., Hoerr R. Influence of the severity of cognitive impairment on the effect of the ginkgo biloba extract EGb 761 in Alzheimer's disease. Neuropsychobiology. 45:2002;19-26.
29. Jantzen P.T., Connor K.E., DiCarlo G., et al. Microglial activation and beta-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci. 22:2002;2246-2254.
30. Hord A., Katz J. COX-2 technology a new approach to perioperative pain management . Anesthesiol News. 18:2000;11-18.
31. McGahan L. COX-2 inhibitors a role in Alzheimer's disease? Issues Emerg Health Technol. Dec:1999;1-6.
32. Reiriz J., Holm P.C., Alberch J., Arenas E. BMP-2 and cAMP elevation confer locus coeruleus neurons responsiveness to multiple neurotrophic factors. J Neurobiol. 50:2002;291-304.
33. Frenkel D., Solomon B. Towards Alzheimer's beta-amyloid vaccination. Biologicals. 29:2001;243-247.
34. Solca M., Salvo I., Russo R., Fiori R., Veschi G. Anaesthesia with desflurane-nitrous oxide in elderly patients. Comparison with isoflurane-nitrous oxide. Minerva Anestesiol. 66:2000;621-626.
35. Muravchick S. Anaesthesia for the aging patient. Can J Anaesth. 40:(5):1993;R63-73. (Pt 2).
36. Paxton J.W., Briant R.H. Alpha 1-acid glycoprotein concentrations and propranolol binding in elderly patients with acute illness. Br J Clin Pharmacol. 18:1984;806-810.
37. Veering B.T., Burm A.G., Vletter A.A., van den Hoeven R.A., Spierdijk J. The effect of age on systemic absorption and systemic disposition of bupivacaine after subarachnoid administration. Anesthesiology. 74:1991;250-257.
38. Sharrock N.E. Epidural anesthetic dose responses in patients 20 to 80 years old. Anesthesiology. 49:1978;425-428.
39. Sprung J., Ogletree-Hughes M.L., Moravec C.S. The effects of etomidate on the contractility of failing and nonfailing human heart muscle. Anesth Analg. 91:2000;68-75.
40. Kharasch E.D. Metabolism and toxicity of the new anesthetic agents. Acta Anaesthesiol Belg. 47:1996;7-14.